Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | — |
| Operating income | -$7.79M | -$16.2M | -$20.2M | -$17.0M | -$24.3M |
| Net income | -$12.6M | -$15.8M | -$19.8M | -$23.3M | -$22.4M |
| EPS (diluted) | -$2.37 | -$1.75 | -$1.49 | -$1.05 | -$0.70 |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | -$4.12M | -$12.1M | -$13.1M | -$15.7M | -$18.8M |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $11.3M | $12.0M | $7.57M | $10.2M | $9.70M |
| Total liabilities | $2.15M | $3.51M | $7.09M | $6.52M | $7.33M |
| Shareholders' equity | $9.18M | $8.51M | $478K | $3.63M | $2.38M |
| Retained earnings | -$28.4M | -$44.2M | -$64.0M | -$87.2M | -$110M |
| Shares (wtd avg diluted) | 5.28M | 9.28M | 13.3M | 22.2M | 32.1M |
Every figure is extracted from MAIA Biotechnology, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.